Dew, with ENTA making new highs again I wanted to ask, any chance this move is more than just Mavyret scrips? I know we are expecting EDP-305 data in October with AASLD. Expecting single titles on PBC, PSC & NASH I believe.
ENTA—Mavyret scripts for week ending 10/6/17 (according to IMS)….
TRx: 526, +6.7% vs prior week NRx: 351, +2.0% vs prior week
We are now ten weeks into the US launch, and the phenomenal week-over-week growth rates seen in prior weeks appear to be moderating.
(As previously noted, Mavyret’s absolute script numbers reported by IMS are low because IMS misses much of the public sector of the HCV market that ABBV is targeting.)
News 
Market Data 
Discover 
AI
